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Quantitative sensory testingThe tyrosine kinase receptor c-Kit is critically involved in the modulation of nociceptive sensitivity in
mice. Ablation of the c-Kit gene results in hyposensitivity to thermal pain, whereas activation of c-Kit
produces hypersensitivity to noxious heat, without altering sensitivity to innocuous mechanical stimuli.
In this study, we investigated the role of c-Kit signaling in human pain perception. We hypothesized that
subjects treated with Imatinib or Nilotinib, potent inhibitors of tyrosine kinases including c-Kit but also
Abl1, PDFGFRa, and PDFGFRb, that are used to treat chronic myeloid leukemia (CML), would experience
changes in thermal pain sensitivity. We examined 31 asymptomatic CML patients (14 male and 17
female) receiving Imatinib/Nilotinib treatment and compared them to 39 age- and sex-matched healthy
controls (12 male and 27 female). We used cutaneous heat and cold stimulation to test normal and nox-
ious thermal sensitivity, and a grating orientation task to assess tactile acuity. Thermal pain thresholds
were significantly increased in the Imatinib/Nilotinib-treated group, whereas innocuous thermal and tac-
tile thresholds were unchanged compared to those in the control group. In conclusion, our findings sug-
gest that the biological effects of c-Kit inhibition are comparable in mice and humans in that c-Kit activity
is required to regulate thermal pain sensitivity but does not affect innocuous thermal and mechanical
sensation. The effect on experimental heat pain observed in our study is comparable to those of several
common analgesics; thus modulation of the c-Kit pathway can be used to specifically modulate noxious
heat and cold sensitivity in humans.
 2014 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved.1. Introduction
Heat pain threshold is often used as a clinical outcome measure
of analgesic efficacy in human patients [3,8,16,55]. Heat pain
threshold varies among individuals, but there is evidence that this
variation is partly determined by genetic factors [35]. Inflamma-
tion and injury lead to mechanical and heat hyperalgesia in
humans, and the latter is primarily due to the sensitization of
primary afferent nociceptors [57]. Nerve growth factor (NGF) not
only regulates the development of nociceptors [27] but is also an
important regulator of their functional properties in adults[17,28,47]. By binding to its high-affinity receptor tyrosine kinase
(RTK), trkA, NGF can acutely sensitize sensory neurons to heat
and capsaicin [14,46]. NGF produces rapid heat hyperalgesia when
injected [11,43], and increases the number of sensory neurons that
respond to noxious heat [52]. The physiological levels of NGF in the
adult organism also set the thermal sensitivity of nociceptors [24].
NGF is not the only growth factor that can regulate the functional
properties of C-fibers. Another RTK, c-RET, also regulates the func-
tional properties of heat-sensitive IB4-positive nociceptors that, in
the adult animal, do not express trkA receptors [29,50,53]. The
c-RET receptor binds glial-derived nerve growth factor (GDNF);
in concert with its co-receptor GFRalpha2, it can form a receptor
for neurturin, a factor that regulates the heat sensitivity of IB4
positive nociceptors [53]. Recently, another signaling system, stem
cell factor (SCF) and its RTK receptor c-Kit, was shown to regulate
nociceptor function [31]. The c-Kit receptor is expressed by a small
number of developing sensory neurons [18,22], and this expression
is maintained in about 20% of adult sensory neurons [31]. Genetic
Table 1
Demographic characteristics of study patients.
Patient Sex Age (y) Treatment Daily dose (mg)
1 Female 67 Imatinib 400
2 Male 69 Nilotinib NA*
3 Female 42 Imatinib 400
4 Male 33 Imatinib 400
5 Male 56 Imatinib 400
6 Female 37 Imatinib 500
7 Female 59 Nilotinib 800
8 Male 53 Imatinib 400
9 Male 49 Nilotinib 800
10 Female 44 Imatinib NA*
11 Female 40 Imatinib 400
12 Female 63 Nilotinib 200
13 Male 35 Nilotinib 800
14 Female 72 Inno-406 480
15 Male 60 Imatinib 400
16 Male 67 Nilotinib 400
17 Male 35 Nilotinib 400
18 Male 35 Imatinib 600
19 Female 32 Imatinib 400
20 Female 41 Imatinib 400
21 Female 46 Imatinib 400
22 Male 62 Nilotinib 800
23 Female 65 Imatinib/Nilotinib NA*
24 Male 43 Imatinib 800
25 Male 54 Nilotinib 600
26 Male 46 Nilotinib 600
27 Female 48 Imatinib 400
28 Male 67 Imatinib 400
29 Female 46 Imatinib 400
30 Male 39 Imatinib 400
31 Male 71 Imatinib 400
* NA, information on exact daily dose not available. Estimated daily dose based on
study sample: 400 to 800 mg (Imatinib) or 200 to 800 mg (Nilotinib).
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noxious heat, paralleled by reduced heat sensitivity of nociceptive
C-fibers [31]. Activation of the c-Kit receptor using its natural
ligand SCF produced marked heat hyperalgesia, without altering
the behavioral response of mice to innocuous mechanical stimuli.
In humans, c-Kit/SCF signaling is best known for controlling the
proliferation, survival, differentiation, and migration of mast cells,
hematopoetic stem cells, melanocytes, and germ cells [2,5,37].
Mutations in the c-Kit transduction pathway are strongly linked
to the occurrence of malignant tumors, including gastrointestinal
stromal tumors [42,56,59]. Small-molecule c-Kit tyrosine-kinase
inhibitors have proved very effective for the treatment of these
tumors [10,19]. In chronic myeloid leukemia (CML), a reciprocal
translocation between chromosomes 9 and 22 results in the
chimeric fusion protein BCR-ABL. BCR-ABL is characterized by a
deregulated activity of the Abelson tyrosine kinase, a highly
oncogenic protein responsible for the development of the disease
[26,44]. Imatinib (Glivec, Novartis) and Nilotinib (Tasigna,
Novartis), are tyrosine-kinase inhibitors used as first-line
treatment in CML. Nilotinib is also used to treat CML patients with
intolerance to or resistance against other tyrosine kinase inhibitors
[1]. Imatinib and Nilotinib also potently inhibit the c-Kit kinase
[6,39]. Because Imatinib and Nilotinib are routinely used for CML
therapy at doses that inhibit the c-Kit receptor, we designed a
study to determine whether such treatments are associated with
analgesia in humans.
2. Methods
2.1. Study participants
A total of 31 ambulant, asymptomatic, chronic-phase CML
patients (17 male, 14 female; mean age 49.7 ± 2.2 years) were
recruited and tested as outpatients at the Campus Virchow
Klinikum, Charité Universitätsmedizin, Berlin, Germany. A cohort
of disease-free age-matched controls (mean age 51.6 ± 1.3 years;
not significantly different from the CML cohort, P = .36, Student t
test) were recruited in parallel, in total 39 healthy male and female
individuals (12 male and 27 female, not significantly different from
the CML cohort, v2 P = .22). Study participants did not have medi-
cal conditions known to affect temperature or touch sensitivity
(diabetes mellitus, polyneuropathy, multiple sclerosis, stroke,
endogenous psychosis and other major psychiatric disorders,
alcohol disease, major liver and kidney disorders), nor were they
receiving treatment known to affect temperature and touch sensi-
tivity (painkillers, antipsychotic drugs, epilepsy drugs, chemother-
apeutics, chronic dialysis). Written informed consent was obtained
in accordance with the Declaration of Helsinki, and the study was
approved in full by the Charité Ethics Committee. CML patients in
this study were receiving Imatinib or Nilotinib treatment, apart
from 1 female patient who was on a 480-mg daily dose of a
new-generation tyrosine kinase inhibitor INNO-406 (Table 1).
Because INNO-406 and Imatinib/Nilotinib exhibit similar affinity
for the c-Kit receptor [23], this patient was included in the study
pool. Of the remaining 30 patients, 21 (9 male and 12 female) were
receiving Imatinib treatment (mean daily dose, 480 mg; Table 1),
and 9 (7 male, 2 female) were receiving Nilotinib treatment (mean
daily dose 600 mg; Table 1). Only those patients on stable drug
treatment for more than 2 months were included in the study.
2.2. Assessment of pre-existing occasional pain
Prevalence and degree of pre-existing occasional pain were
assessed using a short questionnaire addressing occurrence, type,
intensity, anatomical site, and duration of any type of occasionalpain over the last 12 months (eg, headache, neck and shoulder
pain, back pain, joint pain, or pain in other body regions). In
addition, subjects were asked to rate their current pain state on
an 11-point numerical rating scale (NRS; 0 = no pain, 10 = worst
pain imaginable).
2.3. Tactile acuity determination
We used a grating orientation task to assess the subject’s tactile
acuity [4]. Subjects were asked to name the orientation of grooved
surfaces lightly pressed against the distal phalanx of the index fin-
ger and the little finger. This test is considered to be a rigorous
measure of passive tactile spatial acuity, in that it requires the sub-
ject to distinguish between 2 stimuli that differ only in respect to
spatial orientation, whereas the applied contact area, force, and
pressure are kept constant, thereby avoiding nonspatial cues that
might bias the outcome [20]. We followed the procedure as previ-
ously described [4] and as subsequently applied by us in genetic
studies [13]. Briefly, square-wave gratings of equal groove and
ridge widths were placed on the distal finger segment either paral-
lel or transverse to the axis of the finger, and subjects, with their
eyes closed, were asked to report the orientation of the stimulus.
A cube with 6 grating widths (1 per surface) ranging from 6 to
0.75 mm was used for stimulus presentation. Beginning with the
easiest detectable grating orientation, the grating width was
stepped down after 2 sequential correct responses, and stepped
up after a single incorrect response. The test was terminated after
the 13th reversal point, with average of gratings widths at reversal
points 4 through 13 taken as the individual tactile acuity threshold,
that is. the width of the grooves with orientations that the subject
could reliably perceive, which is inversely related to tactile spatial
acuity.
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Thermal sensitivity was measured using the TSA-II Thermal
Sensory Analyzer (Medoc Advanced Medical Systems, Ramat
Yishai, Israel). A 30  30-mm thermode, with a baseline temper-
ature of 32C was placed in full contact on the volar aspect of
the left forearm. For assessment of innocuous thermal sensitivity
(ie, detection threshold), the temperature first gradually
decreased, then increased, and subjects were asked to press a
button as soon as they perceived the temperature shift from
neutral to cold and from neutral to warm, respectively. Detection
thresholds were determined 4 times, and the average was taken
for analysis. Next, thermal heat and cold pain thresholds were
assessed. The testing procedure was the same as for innocuous
thermal sensitivity, except that subjects were now asked to press
the button as soon as they experienced the temperature shift
from hot to painfully hot, and from cold to painfully cold, respec-
tively. Pain thresholds were determined 3 times, and the average
was taken for analysis.2.5. Animal experiments
All animal experiments were performed in adult female C75BL/
6 mice (20–25 g) (Charles River Laboratories, Willmington, MA) in
accordance with the National Academy of Science ‘‘Guide for the
Care and Use of Laboratory Animals,’’ and were approved by the
local animal care committee (Landesamt für Arbeitsschutz, Ges-
undheitsschutz und Technische Sicherheit, Berlin, Germany). Ani-
mals were housed 6 per cage with a bedding of wood sawdust and
maintained on a 12-hour light/dark cycle (light on 8 AM to 8 PM),
with free access to food pellets and water. Animals were treated
with Imatinib mesylate or Nilotinib (both Sequoia Research Prod-
ucts, Pangbourne, UK). Both drugs were diluted in 10% dimethyl
sulfoxide (DMSO; in 1 phosphate-buffered saline solution). Con-
trol animals received 10% DMSO (in 1 PBS). Solutions were
administered in a volume of 100 lL by means of a straight animal
ball-tipped feeding needle (oral gavage [p.o.]). The needle was
introduced into the mouth laterally, the solution injected, and
the needle gently withdrawn. Drug and vehicle were adminis-
trated in the morning, and sensory testing was performed in the
afternoon of the same day. Paw withdrawal latency to thermal
noxious stimuli was measured using the Hargreaves radiant-heat
plantar test (IITC Life Science, Woodland Hills, CA). Animals were
placed in elevated Plexiglas chambers (10  10  22.5 cm; tem-
pered glass surface) and allowed to acclimate. A high-intensity
light beam was focused onto the plantar surface of the hind
paw. The intensity of the stimulus was adjusted to achieve an
average baseline paw withdrawal latency of approximately 4 to
6 seconds in naive mice. The cut-off time was 20 seconds to pre-
vent tissue damage. Quick hind paw withdrawals from the hot
beam (with or without licking of the hind paw), after calm behav-
ior before testing, were counted as a response. Paw movements
associated with locomotion or weight shifting were not included.
Baseline values were taken once a day for 3 days. During each ses-
sion, paw withdrawal latency was determined for both paws, 5
times per paw. Sensitivity to mechanical stimuli was measured
using the dynamic plantar aesthesiometer (Ugo Basile, Milan,
Italy). Animals were placed in elevated chambers (15  15 
22.5 cm; wire mesh floor) and allowed to acclimate. A small-diam-
eter, blunt metallic filament was applied onto the plantar surface
of the hindpaw with an increasing force (0.5 g/s with a maximum
of 20 g for 10 seconds). The force at which animals showed paw
withdrawal (see above) was recorded. Baseline values were taken
on 3 consecutive days. Paw withdrawal latency was determined
for both paws, 3 times per paw.2.6. Statistical analysis
Data are presented as mean ± standard error of the mean (SEM).
The nonparametricMann–WhitneyU test (1-sided P value,a = .025)
was used to compare thermal and tactile data, age distribution, and
pre-existing pain states among groups. Thev2 testwas used to com-
pare sex distribution and occurrence of pre-existing occasional pain.
3. Results
In a previous study, we had obtained some evidence that Imati-
nib treatment of mice leads to an elevation in baseline heat pain
threshold [31]. However, because the majority of CML patients
are now treated with the second-generation tyrosine kinase
inhibitors [1], we tested the effects of oral dosing of Imatinib and
Nilotinib on baseline heat and mechanical pain thresholds in mice.
We found that oral dosing with Imatinib and Nilotinib produced a
robust and significant elevation of the paw withdrawal latency to
radiant heat (Fig. 1A). The elevation of paw withdrawal threshold
was statistically significant on the fourth day after Imatinib admin-
istration and on the third day after oral dosing with nilotinib
(P < .05 with an analysis of variance with post hoc Bonferroni test).
The same animals were also tested for changes in the force
required to evoke paw withdrawal using a dynamic plantar esthe-
siometer, but there was no significant effect of either Imatinib or
Nilotinib treatment on paw withdrawal threshold (Fig. 1B).
We next investigated, in a group of asymptomatic chronic-
phase CML patients, the effects of prolonged exposure to a c-Kit
tyrosine kinase inhibitor on thermal pain sensitivity, and normal
thermal and tactile sensation.
General current pain state, and prevalence and degree of occa-
sional pain, were comparable between groups. General current
pain state was rated 1.83 ± 0.33 NRS in the Imatinib/Nilotinib-trea-
ted group, compared to 1.41 ± 0.27 NRS in controls (P > .40; Mann–
Whitney U test). In the Imatinib/Nilotinib-treated group, 34% of
subjects reported the existence of occasional pain in the last
12 months (compared to 56% in controls, P > .40; v2 test).
3.1. Imatinib/Nilotinib treatment is associated with decreased
sensitivity to painful thermal stimuli
Both heat and cold pain threshold were significantly elevated in
the Imatinib/Nilotinib-treated group (Fig. 2A). Mean heat pain
threshold was 46.58C ± 0.31C in the Imatinib/Nilotinib-treated
group compared to 45.22C ± 0.31C in controls (P < .005; Mann-
Whitney U test). Mean cold pain threshold was 7.69C ± 1.53C in
the Imatinib/Nilotinib-treated group compared to 11.96C ± 1.50C
in controls (P < .05; Mann-Whitney U test). We also investigated
whether the higher daily doses were associated higher thermal
thresholds for heat and cold pain, respectively. We did in fact
observe that higher heat pain thresholds were associated with
increasingdose, and that coldpain thresholdswere lower inpatients
treated with higher daily doses of Imatinib, nilotinib, or INNO-406
(Fig. 2B, C). Thus there was a significant correlation between heat
and cold pain threshold and daily dose (Spearman correlations for
heat pain r = 0.39, for cold pain r = 0.35; P < .05 1-sided compari-
son).We also investigatedwhether disease duration correlatedwith
increases in heat or cold pain thresholds, butwe foundno significant
correlation in our dataset (Spearman correlations for heat pain
r = 0.036, P > .2, for cold pain r = 0.012, P > .2).
3.2. Imatinib/Nilotinib treatment does not affect innocuous
thermosensation
Sensitivity to innocuous warming and cooling, expressed as
absolute change (D) from the baseline temperature (32C), did
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Fig. 1. Effect of Imatinib and Nilotinib on acute noxious thermal and mechanical sensitivity in mice. (A) Attenuated sensitivity to noxious thermal stimulation (Hargreaves
radiant heat) in adult female C75BL/6 mice treated orally with Imatinib (left panel; 0.1 mg/g per day, n = 24 animals per group) or Nilotinib (right panel; 0.1 mg/g per day,
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threshold wasD 1.99C ± 0.29C in the Imatinib/Nilotinib-treated
group, compared to D 1.46C ± 0.20 in the control group (P > .15;
Mann–Whitney U test). Warm detection threshold was D
+2.25C ± 0.21 in the Imatinib/Nilotinib-treated group, compared
to D +1.90C ± 0.24C in the control group (P >.30; Mann–Whitney
U test).
3.3. Imatinib/Nilotinib treatment does not alter tactile sensitivity
Tactile acuity, as measured using the grating orientation test on
the dominant hand, did not differ significantly between groups.
Tactile acuity threshold was 2.21 ± 0.23 mm in the Imatinib/Niloti-
nib-treated group, compared to 2.11 ± 0.12 mm in controls (P = .84;
Mann–Whitney U test) for the index finger, and was 2.74 ± 0.23
mm in the Imatinib/Nilotinib-treated group compared to
2.36 ± 0.12 mm in controls (P = .25; Mann–Whitney U test) for
the little finger (Fig. 3B).
4. Discussion
In this study, we have shown that inhibition of c-Kit activity, via
prolonged treatment with the tyrosine-kinase blocker Imatinib or
Nilotinib, is associated with decreased sensitivity to painful heat
and cold in humans. In contrast, discrimination of non-noxious
thermal stimuli and tactile acuity were not changed in patients
undergoing such treatments. Provided that the underlying biology
of nociceptors in mice and in humans is similar, our previous stud-
ies in mice led us to expect that c-Kit inhibition should lead to an
elevation in heat pain thresholds. Mice treated with Imatinib or
Nilotinib displayed longer latency withdrawal thresholds to nox-
ious heat (Fig. 1A), and the threshold for noxious heat activation
of identified C-fiber nocieptors was also elevated after Imatinib
treatment [31]. The significant elevation in heat pain thresholds
in Imatinib/Nilotinib treated patients was robust and thus consis-tent with the hypothesis that SCF/c-Kit signaling also regulates
heat nociception in humans. In patients undergoing Imatinib/Nil-
otinib treatment, we also found a significant blunting of cold pain
thresholds, a behavior that was not studied in mice [31]. For heat
pain threshold, the majority of studies have demonstrated lower
heat pain thresholds in females than in males as well as clear
age-dependent effects on this trait in humans [12,16]. However,
here we were careful to ensure that the Imatinib/Nilotinib and con-
trol group were closely matched in terms of age and sex.
The most parsimonious explanation of our results is that inter-
ference with c-Kit signaling results in a lowered sensitivity to nox-
ious thermal stimuli, and that c-Kit activity is involved in
maintaining high responsiveness of thermal C-fiber nociceptors.
Interestingly, the sensitizing effect of SCF in mice requires the pres-
ence of the heat-gated ion channel TRPV1 [7,31]. The TRPV1 ion
channel has been very actively pursued as a potential target for
novel analgesic drugs in the past 15 years, and several TRPV1 antag-
onists have been tested for effects on thermosensation in phase I
trials [8,15,25,36,40,41]. A consistent and worrying observation in
such trials is the ability of such drugs to elevate body temperature
[15,36,41]. No such effects have, to our knowledge, been reported
for drugs that block c-Kit activity. Interestingly, the increase in
acute heat pain thresholds in individuals treated with Imatinib/Nil-
otinib was similar to that observed in healthy volunteers upon
administration of several TRPV1 antagonists [8,25,41]. Imatinib is
known to be poorly CNS penetrant [34], and thus it does seem likely
that it may modulate heat pain thresholds solely through a periph-
eral mechanism [31]. Intriguingly, none of the potent TRPV1 antag-
onists so far reported have demonstrably elevated cold pain
thresholds in humans [41]. Our finding here that cold pain thresh-
olds were also elevated in Imatinib/Nilotinib-treated CML patients
suggests that inhibition of c-Kit signaling also has an impact on cold
nociception, independent of TRPV1-dependent mechanisms.
Several clinicallyused analgesics, includingopioids, nonsteroidal
anti-inflammatory drugs (NSAIDS), and selective cyclooxygenase-2
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Fig. 2. Decreased pain sensitivity in subjects treated with Imatinib/Nilotinib.
Subjects treated with the c-Kit inhibitor Imatinib/Nilotinib (solid bars) show
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pain sensitivity in subjects treated with Imatinib/Nilotinib/Inno-406. (Inset)
Spearman correlations values; P values are based on a 1-sided comparison.
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inflammatorypain inhealthyvolunteers [3].Morphinehas alsobeen
shown to increase cold pain thresholds and to lower the magnitude
of pain intensity [9,21,38]. Thus, the effect of c-Kit inhibitors Imati-
nib and Nilotinib on acute thermal pain sensitivity shown in our
study is comparable to those observed in paradigms assessing the
efficacy of some clinically used analgesics on acute pain in healthy
volunteers Fig. 2.
The ultimate goal of effective pain treatment is to treat hyper-
algesia associated with inflammation. However, the main clinically
relevant hyperalgesia is that to mechanical stimuli, so it would be
interesting to see whether, in animal models, c-Kit inhibitors are
effective in the context of inflammatory or neuropathic pain.A recent study with c-KitW-v mice that carry a hypomorphic c-Kit
allele, in which the kinase activity of c-Kit was reduced by 80%,
indicated that c-Kit might play a role in inflammatory and neuro-
pathic pain [54]. Thus c-KitW-v mice exhibited reduced pain behav-
ior in the second phase of the formalin test but showed anomalous
persistent, increased mechanical hypersensitivity on the contralat-
eral side after exposure to sciatic nerve chronic constriction injury,
a phenomenon not seen in control animals [54]. This murine model
cannot be strictly compared to that used by us in our earlier study;
those mice carried complete loss-of-function c-Kit alleles, but
lethality was reversed by an erythropoietin transgene that rescued
c-Kit function in blood cells [31]. It thus appears that the role of
c-Kit in pathophysiological pain states may be complex; neverthe-
less the effects of pharmacological blockade of c-Kit receptors in
neuropathic and inflammatory models remains to be studied. Our
data with orally administered Nilotinib in mice indicates that this
drug has robust effects on pain behavior (Fig. 1).
4.1. C-Kit inhibition and thermal sensitivity
In humans, the sensations of cooling and warming are thought
to be mediated by afferent fibers that are thinly myelinated
Ad-fibers and unmyelinated C-fibers, respectively [45]. In mice,
the c-Kit receptor is expressed in subpopulations of Ad-fibers and
C-fibers; however, the absence of changes in innocuous warming
and cooling sensation in Imatinib/Nilotinib-treated patients sug-
gest that c-Kit is not expressed in sensory afferents relevant to
these sensory qualities. On the other hand, noxious cold pain sen-
sation was significantly blunted in patients undergoing long-term
Imatinib/Nilotinib treatment, which indicates that c-Kit receptors
could play a significant role in cold pain. c-Kit receptors are pre-
dominantly expressed in C-fibers in mice, and there is evidence
in rodents and in humans that many C-fibers start responding to
cold at temperatures appropriate to signal cold pain (eg, <15C)
[45,48,49].
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Tactile acuity, as determined using the grating orientation task,
did not differ significantly between groups (Fig. 3B). Although c-Kit
is expressed on a subpopulation of mechanoreceptive afferents in
the adult dorsal root ganglion, and lack of SCF/c-Kit during devel-
opment results in hypersensitivity of these fibers to mechanical
stimulation, c-Kit activation via SCF does not alter the behavioral
response of adult mice to mechanical stimuli, nor does blocking
of the c-Kit receptor with Imatinib have any effect on the incidence
or functional properties of mechanoreceptors in adult mice [31]. It
has therefore been suggested that SCF/c-Kit signaling is required
during development to set the normal function of mechanorecep-
tors [31]. Lack of significant difference in tactile acuity between
Imatinib/Nilotinib-treated subjects and healthy controls observed
in our study is consistent with the idea that the effects of
c-Kit/SCF signaling occur during development rather than in the
adult organism.
4.3. Off-target effects of Imatinib and Nilotinib
The drugs used to treat CML are broad-range tyrosine kinase
inhibitors with significant inhibition of c-Kit, Abl1, PDFGFRa,
PDFGFRb (platelet-derived growth factor receptors a,b), DDR1,
and DDR2 (discoidin-domain receptors 1 and 2), and CSF-1R (col-
ony stimulating factor–1) [51]. Importantly, Imatinib and Nilotinib
have no described activity in inhibiting tyrosine kinase receptors or
protein kinases that have been implicated in pain, for example,
TrkA and protein kinase C [28,32,51]. There is no published exper-
imental evidence that inhibition of Abl1, DDR1/2, or CSF-1R is asso-
ciated with pain in any context. Two studies have implicated spinal
cord PDGFR signaling in the development of tactile allodynia asso-
ciated with neuropathic pain in animals [30,33], and a third study
has implicated central PDGFR signaling in the development of mor-
phine tolerance [58]. None of these studies provide evidence that
PDGFR signaling is directly involved in modulating heat and cold
pain sensitivity.
4.4. Conclusion
In conclusion, this is the first study to show the effect of pro-
longed c-Kit inhibition on acute pain perception in humans. We
suggest that interfering with c-Kit signaling is associated with low-
ered thermal and cold pain sensitivity, without altering normal
thermal and tactile sensitivity. An obvious limitation of this study
is that we assessed the effect of c-Kit inhibition on pain perception
in a group of patients with chronic myeloid leukemia rather than
testing the effects in healthy subjects. We included only asymp-
tomatic, chronic phase CML patients in remission in our study, as
ascertained by stringent inclusion criteria equally applied to both
groups, which ensured that the groups did not significantly differ
on any study-relevant parameters. Imatinib/Nilotinib are known
to target kinases other than c-Kit at clinically relevant levels, most
notably the BCR-ABL kinase, whose proliferation it inhibits in CML
treatment. It is worth considering that the effect of Imatinib/Niloti-
nib on thermal pain sensitivity might be exerted through one of
these alternative pathways, or that these targets contribute, to
some extent, to the analgesic properties of these drugs. However,
Imatinib, Nilotinib, and INNO-406 targets other than c-Kit have
been thoroughly described [51], and there is, at present, no
evidence suggesting that they are involved in modulating pain per-
ception. It is possible that novel analgesic medication based on the
nerve growth factor sequestration enters routine clinical use
[17,28,47]. Our study findings make it clear that the sensory conse-
quences of treatment with tyrosine kinase inhibitors such as Imati-
nib and Nilotinib may overlap with anti–nerve growth factormedications, and this should be taken into account when prescrib-
ing such drugs.
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